# Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer

> **NCT02923180** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 33 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Enoblituzumab

## Key facts

- **NCT ID:** NCT02923180
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-02-14
- **Primary completion:** 2020-08-11
- **Final completion:** 2026-07
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2025-07-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02923180

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02923180, "Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02923180. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*